Ava closes $30m Series B Funding Round


Ava reports over 10’000 pregnancies among users. Today, the startup has raised $30 million in a strategic Series B funding round. The funding will fuel R&D to expand product offering beyond fertility into pregnancy and contraception.


The majority of Ava’s new financing came from existing investors, with prominent European VC firms btov and SVC also joining the round. Ava will use the new funds for further product research and development to enhance the existing product and create new applications that empower women to take control of their reproductive health via data insights and science.

In addition to closing the financing round, Ava announced that its cycle-tracking sensor bracelet has officially reached a milestone of 10,000 pregnancies among users since launching in July 2016. The startup reports that this number is growing by 20 per day.

“Ava’s long-term vision is to accompany women through all stages of their reproductive life by providing data-driven, clinically proven technology that will make a woman’s life easier, healthier and better -- be it when they just want to understand their body, while they are trying to prevent pregnancy, trying to get pregnant, are pregnant or entering menopause,” Pascal Koenig Co-Founder.

Ava's fertility tracker is a wearable bracelet that uses sensor technology, clinical research, and data science to precisely monitor the woman’s menstrual cycle or pregnancy in real time. The bracelet relies on eight other physiological parameters, in addition to temperature and accurately detects the 5.3-day fertile window.

Ava continues to invest heavily in clinical trials with the University Hospital of Zurich under the direction of Prof. Brigitte Leeners to study applications of the Ava technology among women trying to get pregnant, suffering from fertility challenges, and to understand complications during pregnancy. Last year, Ava also hired its first Chief Medical Officer, renowned Bayer Schering veteran Maureen Cronin, to help shepherd the company through clinical and regulatory processes involved in new product development, particularly in the area of contraceptives.

“It’s exciting to work with a company that is literally reshaping the way we think about menstrual cycles, hormones and women’s health,” said Prof. Leeners. “Combining the best in science, data insights and technology is not only helping to create families, but improving women’s lives around the world.”

(Press release)